THE COST OF ANTIRETROVIRAL THERAPY IN THREE CENTRAL AMERICAN COUNTRIES

Author(s)

Becker R, Zaccagnini P, Rattana S, Ovation Research Group, Highland Park, IL, USA

OBJECTIVE: Brazil's universal access to HIV treatment and drug price reductions have affordably treated large segments of the country's HIV-infected population. Several countries in Central America have large HIV-infected populations without access to care. This analysis examines the feasibility of applying Brazil's universal access to treatment and drug price reductions given the economic conditions in three Central American countries: Guatamala (n=71,050), El Salvador (n=19,400), and Belize (n=2,400). METHODS: Each country's HIV population not currrently receiving antiretroviral therapy was estimated. For each population, the cost of two-drug and three-drug combination antiretroviral therapy was estimated by applying 2000 Brazilian prices (in U.S. dollars). The ratio of drug costs to gross domestic product was determined to measure each country's relative ability to pay for the cost of treatment. The Brazilian rate of cost savings from averted hospitalizations was subtracted from each country's drug cost estimates to determine total cost of treatment. RESULTS: In Guatamala, the drug costs for treating the HIV population ranges between $54.2 (0.117% of GDP) and $335.1 (0.725%) million depending on whether double or triple combination therapy is used. The costs range between $14.8 (0.062%) and $91.5 (0.381%) million in El Salvador, and between $1.8 (0.232%) and $11.3 (1.433%) in Belize. Potential hospitalization costs averted were $80.5 million in Guatamala, $22.0 million in El Salvador, and $2.7 million in Belize. Given these costs averted, the total cost of treatment ranges between -$28.5 (cost savings) and $252.4 million in Guatamala depending on whether double or triple combination therapy is used, between -$7.9 and $68.8 million in El Salvador, and between -$888.8 thousand and $8.6 million in Belize. CONCLUSIONS: Since the ratio of antiretroviral drug costs to GDP was 0.041% in Brazil in 2000, these three Central American countries may have more difficulty affording antiretroviral therapy unless double combination therapy is used.

Conference/Value in Health Info

2002-05, ISPOR 2002, Arlington, VA, USA

Value in Health, Vol. 5, No. 3 (May/June 2002)

Code

IN4

Topic

Economic Evaluation

Topic Subcategory

Cost/Cost of Illness/Resource Use Studies

Disease

Infectious Disease (non-vaccine)

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×